Were William E. Rote’s Travere Therapeutics (TVTX) share sales under a Rule 10b5-1 plan?

Yes. The filing specifies the sale was made under a Rule 10b5-1 plan. The written plan was adopted on May 29, 2025, and the May 6, 2026 sale of 2,763 shares also included shares sold to satisfy tax obligations from PSU vesting.

Travere Therapeutics (NASDAQ: TVTX) CRO sells shares after PSU vesting event

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Travere Therapeutics Chief Research Officer William E. Rote reported a mix of equity award activity and a small share sale. On May 4, 2026, 4,250 performance-based restricted stock units converted into common stock after a cumulative FILSPARI net revenue performance criterion was met, and he received a new grant of 8,500 performance-based units. The filing notes that an additional 25% of these units is scheduled to vest on January 31, 2027, contingent on continued service. On May 6, 2026, he sold 2,763 shares of common stock at $43.95 per share under a pre-arranged Rule 10b5-1 trading plan that also covered tax obligations from the vesting. Following the transactions, he directly holds 115,474 common shares.

Insider Trade Summary 10b5-1

Net Seller: 2,763 shares ($121,434)

Net Sell 4 txns

Insider ROTE WILLIAM E.

Role Chief Research Officer

Sold 2,763 shs ($121K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,763	$43.95	$121K
Grant/Award	Performance-based restricted stock units	8,500	$0.00	--
Exercise	Performance-based restricted stock units	4,250	$0.00	--
Exercise	Common Stock	4,250	$0.00	--

Holdings After Transaction: Common Stock — 115,474 shares (Direct, null); Performance-based restricted stock units — 8,500 shares (Direct, null)

Footnotes (1)

On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

Key Figures

Shares sold: 2,763 shares Sale price: $43.95 per share Shares held after transactions: 115,474 shares +4 more

7 metrics

Shares sold 2,763 shares Open-market sale on May 6, 2026 at $43.95 per share

Sale price $43.95 per share Common stock sale on May 6, 2026

Shares held after transactions 115,474 shares Direct common stock holdings following reported transactions

PSUs converted 4,250 units Performance-based restricted stock units converting into common stock on May 4, 2026

PSUs granted 8,500 units Performance restricted stock unit grant dated January 31, 2024

Future PSU vesting 25% of certain PSUs Scheduled to vest on January 31, 2027, contingent on continuous service

Net buy/sell shares -2,763 shares Net share disposition across reported buy/sell transactions

Key Terms

performance restricted stock units, Rule 10b5-1(c), cumulative FILSPARI net revenue, contingent right, +1 more

5 terms

performance restricted stock units financial

"the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares"

Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.

Rule 10b5-1(c) regulatory

"a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

cumulative FILSPARI net revenue financial

"a performance criterion related to cumulative FILSPARI net revenue had been achieved"

contingent right financial

"Each PSU represents a contingent right to receive one share of the Issuer's common stock"

tax obligation financial

"includes the sale of shares to cover the tax obligation that occurred upon the vesting"

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTE WILLIAM E.

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Research Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/04/2026		M⁽¹⁾		4,250	A	$0	118,237	D
Common Stock	05/06/2026		S⁽²⁾		2,763	D	$43.95	115,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance-based restricted stock units	⁽³⁾	05/04/2026		A⁽¹⁾		8,500		⁽¹⁾	⁽¹⁾	Common Stock	8,500	$0	8,500	D
Performance-based restricted stock units	⁽³⁾	05/04/2026		M⁽¹⁾			4,250	⁽¹⁾	⁽¹⁾	Common Stock	4,250	$0	4,250	D

Explanation of Responses:

1. On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

2. This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

3. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Travere Therapeutics (TVTX) report for William E. Rote?

William E. Rote reported both equity award activity and a small sale. He converted 4,250 performance-based restricted stock units into common stock, received a grant of 8,500 performance units, and sold 2,763 common shares at $43.95 each in an open-market transaction.

How many Travere Therapeutics (TVTX) shares did William E. Rote sell and at what price?

Rote sold 2,763 shares of Travere Therapeutics common stock at $43.95 per share. The filing states this was an open-market sale executed under a Rule 10b5-1 trading plan, and it included shares sold to cover tax obligations from recent PSU vesting.

What performance-based stock units did William E. Rote receive from Travere Therapeutics (TVTX)?

Rote was granted performance restricted stock units covering 8,500 shares. The PSUs were granted January 31, 2024, with vesting tied to performance criteria, including cumulative FILSPARI net revenue, and additional vesting linked to accelerated milestone achievement and retention objectives.

Which Travere Therapeutics (TVTX) performance milestone triggered William E. Rote’s PSU vesting?

Vesting was triggered by a cumulative FILSPARI net revenue performance criterion. On May 4, 2026, 50% of the performance restricted stock units vested after confirmation that this revenue target was achieved following the release of results for the quarter ended March 31, 2026.

How many Travere Therapeutics (TVTX) shares does William E. Rote hold after these transactions?

After the reported transactions, Rote holds 115,474 common shares directly. This figure reflects his position after converting 4,250 performance-based restricted stock units into common stock and selling 2,763 shares under his Rule 10b5-1 trading plan.

When will additional Travere Therapeutics (TVTX) PSUs vest for William E. Rote?

An additional 25% of certain PSUs is scheduled to vest on January 31, 2027. This future vesting is contingent on the timing of the cumulative FILSPARI net revenue milestone achievement and Rote’s continuous service with Travere Therapeutics through that date.